API | xiyanping

xiyanping Report issue

Small molecule Experimental

AACT

Active Ingredient History

NOW

Xiyanping (喜炎平) is an anti-inflammatory and antiviral preparation developed and licensed for use in China. It is a semi-synthetic injectable product derived from the active component of the plant Andrographis paniculata, which is used in Traditional Chinese medicine. Xiyanping is primarily composed of 9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate. It is used mainly in the treatment of hand, foot and mouth disease, diarrhea, upper respiratory tract infections and viral pneumonia, though one case report suggested it may also be useful in the treatment of Zika fever. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

xiyanping

Organizations (15)

Research & Development (15)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (1)

Inflammation

Experimental Indications - Clinical Trial Phases 1-4 (2)

Bronchitis (Phase 4)

Inflammation ()

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial Organizations: 15

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue